JFS Wealth Advisors LLC Sells 583 Shares of Kenvue Inc. (NYSE:KVUE)

JFS Wealth Advisors LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 16.4% during the fourth quarter, HoldingsChannel reports. The firm owned 2,978 shares of the company’s stock after selling 583 shares during the quarter. JFS Wealth Advisors LLC’s holdings in Kenvue were worth $64,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in KVUE. AMF Tjanstepension AB raised its position in Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock worth $2,787,000 after acquiring an additional 78,540 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Kenvue by 13.4% in the 3rd quarter. Vontobel Holding Ltd. now owns 22,594 shares of the company’s stock valued at $523,000 after purchasing an additional 2,677 shares during the period. Capital Investment Advisors LLC lifted its stake in Kenvue by 11.9% in the 3rd quarter. Capital Investment Advisors LLC now owns 11,309 shares of the company’s stock valued at $262,000 after purchasing an additional 1,201 shares during the last quarter. Everence Capital Management Inc. bought a new position in Kenvue during the third quarter worth about $473,000. Finally, Sequoia Financial Advisors LLC increased its position in Kenvue by 6.2% during the third quarter. Sequoia Financial Advisors LLC now owns 24,690 shares of the company’s stock worth $571,000 after buying an additional 1,449 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.3 %

NYSE KVUE opened at $22.00 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $42.17 billion, a price-to-earnings ratio of 41.50, a PEG ratio of 2.16 and a beta of 1.45. The company has a 50 day moving average of $21.30 and a 200-day moving average of $22.12. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.73%. Kenvue’s dividend payout ratio is 154.72%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KVUE. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Bank of America upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.